Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | JAK3 |
| Variant | A573V |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | JAK3 A573V lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). A573V results in constitutive phosphorylation of Jak3, activation of downstream Stat5 and Erk, is transforming in cultured cells (PMID: 18755984, PMID: 29046866, PMID: 28284718), and induces T-cell acute lymphoblastic leukemia in mouse models (PMID: 25193870). |
| Associated Drug Resistance | |
| Category Variants Paths |
JAK3 mutant JAK3 act mut JAK3 A573V |
| Transcript | NM_000215.4 |
| gDNA | chr19:g.17837197G>A |
| cDNA | c.1718C>T |
| Protein | p.A573V |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000215 | chr19:g.17837197G>A | c.1718C>T | p.A573V | RefSeq | GRCh38/hg38 |
| NM_000215.4 | chr19:g.17837197G>A | c.1718C>T | p.A573V | RefSeq | GRCh38/hg38 |
| XM_047438786.1 | chr19:g.17837197G>A | c.1718C>T | p.A573V | RefSeq | GRCh38/hg38 |
| NM_000215.3 | chr19:g.17837197G>A | c.1718C>T | p.A573V | RefSeq | GRCh38/hg38 |
| XM_011527991.3 | chr19:g.17837197G>A | c.1718C>T | p.A573V | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK3 A573V | hematologic cancer | sensitive | Tofacitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xeljanz (tofacitinib, CP-690,550) decreased cell viability in transformed mouse Ba/F3 cells expressing Jak3 A573V (PMID: 29046866). | 29046866 |